Rigin
An immunomodulatory tetrapeptide derived from human IgG, used in cosmeceuticals as Palmitoyl Tetrapeptide-7 to suppress skin inflammation (IL-6) and support anti-aging skin repair.
What is Rigin?
Rigin (Gly-Gln-Pro-Arg) is a tetrapeptide originally isolated from the heavy chain of human immunoglobulin G (IgG) in 1981. It was discovered as a structural analog of tuftsin, with equivalent phagocytosis-stimulating activity. In its lipidated form — Palmitoyl Tetrapeptide-7 (formerly Palmitoyl Tetrapeptide-3) — it is widely used in cosmeceutical skincare as an anti-inflammatory peptide. Its primary function in skincare is not collagen stimulation but rather suppression of IL-6, a pro-inflammatory cytokine that accelerates skin aging by driving chronic low-grade inflammation. It is commonly combined with Palmitoyl Tripeptide-1 in the commercial complex Matrixyl 3000 for synergistic anti-aging effects.
What Rigin Is Investigated For
Rigin is investigated primarily as a cosmeceutical anti-inflammatory peptide — specifically via its palmitoylated form (Palmitoyl Tetrapeptide-7) — with ancillary interest in its original immunological role as a phagocytosis-stimulating IgG fragment. The strongest available evidence is the in vitro data from Sederma showing 40–86% IL-6 suppression in keratinocytes, plus limited 12-week clinical data on multi-component Matrixyl 3000 formulations reporting improvements in hydration, elasticity, and collagen density. The honest caveats are substantial: Rigin is almost never studied as a standalone active — most clinical data comes from multi-ingredient formulations that make attribution difficult, most efficacy work is manufacturer-associated rather than independently replicated, and the chain from in vitro IL-6 suppression to meaningful in vivo anti-aging endpoints in humans is plausible but not rigorously demonstrated. Injectable human use is not established and the immunomodulatory mechanism makes it particularly inadvisable outside a controlled research setting.
History & Discovery
Rigin (Gly-Gln-Pro-Arg) was first identified in 1981 by researchers studying tuftsin, the well-characterized phagocytosis-stimulating tetrapeptide derived from the IgG heavy chain. Rigin was isolated from a different region of human IgG (heavy chain positions 224–227) and shown to share both structural features (a type VII β-turn conformation) and functional activity (phagocytosis stimulation) with tuftsin. The name 'Rigin' reflected its origin in the IgG molecule, and the discovery confirmed a hypothesis that the IgG molecule contains multiple immunomodulatory peptide motifs releasable by proteolytic processing. The peptide remained primarily an immunology research curiosity for two decades — with notable preclinical work on hydrophobic Rigin analogs showing protective effects against Plasmodium berghei malaria in mice via lymphocyte activation pathways — until Sederma (a Croda subsidiary in France) developed the palmitoylated form (Pal-GQPR, INCI palmitoyl tetrapeptide-7, formerly palmitoyl tetrapeptide-3) for cosmeceutical use. The cosmetic positioning was anti-inflammatory rather than collagen-stimulating: Sederma's in vitro work in keratinocytes demonstrated that Pal-GQPR suppresses IL-6 secretion, reducing the chronic low-grade inflammation ('inflammaging') that drives extracellular matrix degradation and skin aging. Pal-GQPR became most widely known as one of the two active components in Sederma's Matrixyl 3000 complex (the other being palmitoyl tripeptide-1, Pal-GHK), where the anti-inflammatory and matrikine mechanisms were positioned as complementary.
How It Works
Rigin calms skin inflammation. It suppresses IL-6, a key inflammatory molecule that accelerates skin aging when chronically elevated. UV exposure spikes IL-6, which breaks down collagen and weakens skin structure. Rigin dials down this inflammatory signal, protecting the skin's structural proteins from inflammatory damage. Separately, it also stimulates immune cells (phagocytes) to clear debris and pathogens.
Rigin (Gly-Gln-Pro-Arg) is derived from the Fc region of human IgG heavy chain (positions 224-227). It adopts a type VII beta-turn conformation structurally analogous to tuftsin. In its palmitoylated form (Pal-GQPR), it suppresses IL-6 secretion from keratinocytes — in vitro data shows 40-60% IL-6 reduction at 10-100 μM and up to 86% reduction in UV-irradiated cells. IL-6 drives inflammaging in skin by promoting MMP expression, ECM degradation, and impaired collagen synthesis. By reducing IL-6, Rigin indirectly protects ECM integrity. Additionally, it may inhibit MMP activity and stimulate production of laminin IV/V and collagen VII. The unmodified peptide stimulates phagocytosis at levels comparable to tuftsin, activating macrophage-mediated clearance. Hydrophobic analogs (palmitoyl, cholestanyl) showed immunomodulatory protection against Plasmodium berghei in mice, operating through lymphocyte activation rather than macrophage pathways.
Evidence Snapshot
Human Clinical Evidence
Limited direct clinical data for Rigin alone. A 12-week clinical study of a multi-component eye cream containing Palmitoyl Tetrapeptide-7 showed significant improvements in skin hydration, elasticity, and collagen density, with increased fibroblast proliferation and collagen/elastin synthesis. However, active complexes contained multiple ingredients, making it difficult to attribute effects to Rigin specifically. Widespread cosmeceutical use provides indirect safety evidence.
Animal / Preclinical
Moderate. Hydrophobic Rigin analogs provided significant protection against Plasmodium berghei malaria in mice — prophylactic administration substantially reduced parasitemia and mortality, operating through lymphocyte activation (PMID: 11379040). In vitro data shows dose-dependent IL-6 suppression in keratinocytes and UV-protection effects.
Mechanistic Rationale
Moderate. The IL-6 suppression mechanism is supported by in vitro keratinocyte data from Sederma (the commercial developer). The phagocytosis-stimulating activity is well-established from the original 1981 discovery paper and confirmed by structural studies. The type VII beta-turn conformation has been characterized by NMR and molecular dynamics (PMID: 10691984, 12413862).
Research Gaps & Open Questions
What the current literature has not yet settled about Rigin:
- 01Independent, non-industry-funded human trials on Rigin specifically — most cosmetic efficacy data comes from Sederma-associated Matrixyl 3000 studies, and isolated Pal-GQPR clinical trials are essentially absent.
- 02Attribution within multi-component formulations — because Rigin is almost always used in combination with Pal-GHK (Matrixyl 3000) or other peptides, the unique contribution of Pal-GQPR to clinical endpoints is poorly characterized.
- 03Real-world skin-penetration quantification of Pal-GQPR across commercial formulations — delivery to viable keratinocytes and dermal cells from typical topical products is poorly characterized.
- 04Translation of in vitro IL-6 suppression to in vivo clinical anti-aging endpoints — the mechanistic chain from cytokine modulation in keratinocyte culture to measurable skin-aging outcomes in humans is plausible but not rigorously demonstrated.
- 05Long-term human data — most studies run 8–12 weeks; whether chronic continuous use over years sustains benefit, attenuates, or has any unrecognized signals from sustained immunomodulation has not been studied.
- 06Whether Matrixyl 3000 (Pal-GHK + Pal-GQPR) meaningfully outperforms Pal-GHK alone in robust clinical endpoints — the combination is the dominant commercial form, but head-to-head clinical evidence demonstrating Pal-GQPR adds meaningful benefit beyond Pal-GHK alone is limited.
Forms & Administration
Rigin is primarily used topically as Palmitoyl Tetrapeptide-7 in cosmeceutical formulations (serums, creams, eye treatments). It is commonly formulated at 50-200 ppm in skincare products, often combined with Palmitoyl Tripeptide-1 as Matrixyl 3000. The unmodified peptide is available as a research compound. Topical cosmeceutical use does not require a prescription.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Cosmetic formulations typically include Palmitoyl Tetrapeptide-7 at 50–200 ppm (0.005–0.02%) of the finished product, which is the manufacturer's recommended in-use range and the level used in most commercial Matrixyl 3000-containing products. This is substantially lower than concentrations typical for matrikine peptides (Matrixyl 2–8%) or neuromuscular peptides (Argireline 5–10%) — Rigin operates at the cytokine-modulating end of the dose-response curve.
Frequency
Applied topically once or twice daily to clean skin. Most cosmetic use occurs in finished products applied as part of a regular AM/PM skincare routine. Dedicated trial protocols on Rigin alone are essentially absent; available clinical data comes from multi-component formulations applied for 8–12 weeks before measuring skin endpoints.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Continuous indefinite use. Rigin's IL-6 suppression mechanism operates only while the peptide is present; sustained application is the premise of the anti-inflammaging effect, and benefit recedes with discontinuation. No cycling strategy is described in the cosmetic literature.
Protocol Notes
The palmitoyl modification is the formulation choice that distinguishes Pal-GQPR from a bare tetrapeptide. Palmitic acid conjugation improves partition into the lipid-rich stratum corneum, which is where a small charged tetrapeptide alone would stall. Even so, only a small fraction of applied palmitoyl-GQPR reaches viable epidermis in typical cosmetic formulations — the gap between in vitro IL-6 suppression in keratinocyte culture (40–60% reduction at 10–100 μM, up to 86% in UV-irradiated cells) and in vivo human anti-aging effects partly reflects this delivery bottleneck. In practice, Rigin is almost never used as a standalone active. Its dominant commercial form is the Matrixyl 3000 complex, where it is paired with Pal-GHK (palmitoyl tripeptide-1) on the rationale that Pal-GHK builds collagen via matrikine signaling while Pal-GQPR protects collagen from inflammatory degradation via IL-6 suppression — a 'build and protect' framing. Most clinical efficacy evidence for Pal-GQPR in humans actually comes from Matrixyl 3000 trials, which makes attribution to Rigin specifically difficult. Injectable Rigin is not an established category in humans. The peptide's immunomodulatory and phagocytosis-stimulating properties suggest theoretical caution about injection beyond cosmetic surface use.
Rigin is a cosmetic ingredient, not a drug. It is not FDA-approved to treat or prevent any medical condition, and cosmetic claims permitted on labels are limited to appearance-related language.
Timeline of Effects
Onset
No published trials measure Rigin alone over time. Within Matrixyl 3000-containing products, surface-level smoothing and hydration effects from vehicle ingredients appear within days, while measurable changes in skin firmness, elasticity, and wrinkle endpoints typically begin to emerge at 4–8 weeks of twice-daily application.
Peak Effect
Maximum measured effect from Matrixyl 3000-containing multi-component products is typically reported at 8–12 weeks. A 12-week clinical study of a multi-component eye cream containing Pal-GQPR reported significant improvements in skin hydration, elasticity, and collagen density — but the multi-ingredient formulation makes direct attribution to Rigin specifically difficult.
After Discontinuation
Benefits recede gradually over weeks to months as the peptide is cleared and IL-6 suppression is withdrawn. Skin returns toward its pre-treatment trajectory; no rebound or withdrawal pattern is described.
Common Questions
Who Rigin Is NOT For
- •Broken, irritated, or actively inflamed skin — wait until the skin barrier is intact before applying cosmetic peptide serums; application to compromised skin increases irritation potential and any systemic absorption.
- •Known hypersensitivity to Rigin or to other components of the cosmetic vehicle (preservatives, fragrances, emulsifiers); contact dermatitis is uncommon but reported.
- •Pregnancy and breastfeeding — topical cosmetic use on intact skin is generally considered low-risk, but there is no dedicated safety data in pregnancy, and a conservative default is to minimize biologically active immunomodulatory peptide use during this window.
- •Pediatric use — no data and no clinical reason for children or adolescents to use anti-aging peptides.
- •Active autoimmune skin disease (psoriasis, lupus-related skin disease) on the application area — Rigin's immunomodulatory mechanism (phagocytosis stimulation, cytokine modulation) may be relevant in unpredictable ways. Patients should consult their dermatologist before introducing immunomodulatory peptides on affected skin.
- •Do not inject cosmetic Rigin preparations — these are not sterile injectable products, and the peptide's immune-stimulating properties make injection particularly inadvisable outside a controlled clinical research setting.
Drug & Supplement Interactions
Documented pharmacological drug interactions for topical Rigin are minimal. Systemic absorption from typical topical use is low and the palmitoylated tetrapeptide is not expected to reach clinically relevant plasma levels or interact with oral or injected medications. The relevant interaction space is topical layering with other actives. Rigin is compatible with most cosmetic ingredients — niacinamide, hyaluronic acid, ceramides, and other peptides layer readily. Co-formulation with Pal-GHK (palmitoyl tripeptide-1) is standard via the Matrixyl 3000 complex and is the dominant commercial form of Rigin. Layering with neuromuscular peptides (Argireline, SNAP-8, Syn-Ake) combines independent mechanisms cleanly. Pairing with retinoids is generally compatible and complementary (retinoids drive cell turnover; Rigin modulates inflammatory cytokine signaling). High-concentration L-ascorbic acid (vitamin C) is acidic enough that concurrent same-layer application can destabilize peptide actives and is typically used at a different time of day. Strong AHA/BHA exfoliation on the same evening as Rigin can reduce peptide activity at the surface and increase irritation, so spacing is sensible. No documented concern exists with oral medications, systemic hormones, or anticoagulants at the level of topical cosmetic exposure. Patients on systemic immunosuppressants or biologics for autoimmune disease have no documented interaction with topical Pal-GQPR, but the theoretical immunomodulatory mechanism warrants disclosure to a treating clinician if topical use is on extensive surface area or compromised skin.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved as a drug — marketed as a cosmeceutical ingredient
- • Injectable use is not established for humans
- • Immune-stimulating properties may be contraindicated in certain autoimmune conditions
- • Quality varies across cosmeceutical and research sources
What We Don't Know
Systemic safety of injectable Rigin in humans has not been studied. Long-term topical safety is supported by widespread cosmeceutical use but not by formal clinical trials. The immune-stimulating properties observed in vitro and animal models have not been systematically evaluated in humans.
Legal Status
United States
Regulated as a cosmetic ingredient under FDA cosmetic law, not as a drug. Over-the-counter sale in finished cosmetic formulations is permitted without prescription. Palmitoyl tetrapeptide-7 is INCI-listed and is a major cosmetic ingredient via the Matrixyl 3000 complex used in many over-the-counter and professional anti-aging products. Not approved as a drug for wrinkles, inflammation, or any other medical indication — labels are limited to cosmetic appearance claims.
International
Permitted as a cosmetic ingredient across the EU (CosIng database), UK, Canada, Australia, Japan, and most major markets. CIR (Cosmetic Ingredient Review) has assessed palmitoyl tetrapeptide-7 as safe for cosmetic use at typical formulation levels.
Sports & Competition
Not listed on the WADA Prohibited List and not a realistic doping concern. Topical cosmetic peptides have negligible systemic exposure relevant to performance.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Rigin is a powerful standalone anti-aging peptide.
Reality
Rigin is rarely used standalone in commercial products. Its dominant form is within the Matrixyl 3000 complex, paired with Pal-GHK. Most clinical efficacy data attributed to Rigin actually comes from multi-component formulations, and Rigin's specific contribution to in vivo anti-aging endpoints in humans is not well isolated.
Myth
Matrixyl 3000 is dramatically more effective than the original Matrixyl because it adds Rigin.
Reality
Matrixyl 3000's anti-inflammatory rationale is biologically reasonable in vitro, but head-to-head in vivo clinical data demonstrating that Pal-GHK + Pal-GQPR outperforms Pal-KTTKS or Pal-GHK alone at the level of robust wrinkle-depth or firmness differences is not robust. Marketing positions the 3000 as a clear upgrade; clinical evidence is more equivocal.
Myth
Because Rigin stimulates phagocytosis, topical application boosts skin immunity in a meaningful way.
Reality
The phagocytosis-stimulating activity is well-documented for the unmodified peptide in vitro and in vivo immunology models, but topical Pal-GQPR at cosmetic concentrations is unlikely to produce systemic or clinically meaningful immune effects. The relevant skin mechanism is local IL-6 suppression in keratinocytes, not generalized immune boosting.
Myth
Rigin can be safely injected for stronger effect.
Reality
Cosmetic Pal-GQPR preparations are not sterile injectable products, not manufactured under injectable standards, and have no clinical basis for human injection. Rigin's immunomodulatory and phagocytosis-stimulating properties make injection particularly inadvisable outside a controlled research setting, regardless of cosmetic product availability.
Myth
Rigin is just a copy of tuftsin and the two are interchangeable.
Reality
Rigin and tuftsin share structural features (type VII β-turn) and broadly similar phagocytosis-stimulating activity, but they are distinct peptides from different regions of the IgG molecule with their own research profiles. The cosmetic palmitoylated form (Pal-GQPR) has been developed and marketed independently, and the in vitro keratinocyte IL-6 suppression data comes from Sederma's Pal-GQPR-specific work, not from generalized tuftsin literature.
Published Research
7 studiesThe second life of antibodies.
Determination of an unusual secondary structural element in the immunostimulating tetrapeptide rigin.
Folded conformation of an immunostimulating tetrapeptide rigin: high temperature molecular dynamics simulation study.
Immunomodulatory potential of hydrophobic analogs of Rigin and their role in providing protection against Plasmodium berghei infection.
Characterization of a novel type VII beta-turn conformation for a bio-active tetrapeptide rigin.
Rigin, another phagocytosis-stimulating tetrapeptide isolated from human IgG. Confirmations of a hypothesis.
The 1981 original discovery paper — isolated Rigin from the human IgG heavy chain and demonstrated phagocytosis-stimulating activity, establishing the peptide's foundational immunomodulatory identity.
Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream.
Quick Facts
- Class
- Cosmeceutical Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Moderate Data
- Updated
- Apr 2026
- Citations
- 7PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.